3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Withdrawn
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Conditions
Pain
5
Neoplasms
5
Pain, Intractable
3
Agnosia
3
Pain, Postoperative
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Spinal Stenosis
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Peripheral Nervous System Diseases
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Procedural
1
Neurotoxicity Syndromes
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mucositis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Ketamine
3
Morphine
2
Methadone
2
resiniferatoxin
1
Standard of Care
1
Sodium Chloride
1
Passive Cutaneous Anaphylaxis
1
Hydromorphone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Pain, Intractable
×
Ketamine
×
Clear all
NCT01951911
2017-07-11
KETA-1
Haukeland University Hospital
Phase 3
Withdrawn
NCT01326325
2013-08-07
KEPAL
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
24 enrolled
NCT00484484
2011-05-04
KETADOL
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
100 enrolled